Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C.

Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Abstract Text:

E Tsochatzis,G V Papatheodoridis,E K Manesis,N Chrysanthos,G Kafiri,A J Archimandritis,E Tsochatzis,G V Papatheodoridis,E K Manesis,N Chrysanthos,G Kafiri,A J Archimandritis,

BACKGROUND/AIMS: Hepatic steatosis has not been adequately studied in chronic hepatitis B, while it is considered to be a cardinal feature in chronic hepatitis C and to be mainly metabolically induced in patients infected with genotype 1. We investigated the prevalence of and the parameters associated with steatosis in HBeAg-negative chronic hepatitis B. METHODS: We studied 213 patients with HBeAg-negative chronic hepatitis B and compared them with 163 patients with genotype-1 chronic hepatitis C. Steatosis was semi-quantitatively graded. RESULTS: Steatosis was significantly less frequent in chronic hepatitis B than chronic hepatitis C (60% versus 72%, P=0.016), but there was no difference in the prevalence of moderate/severe steatosis. In chronic hepatitis B, steatosis was associated only with higher body mass index (P=0.002), while moderate/severe steatosis was associated only with higher body mass index (P=0.043) and diabetes (P=0.031). Steatosis was relatively less frequent in chronic hepatitis B than chronic hepatitis C non-diabetic, normal-weight patients (45.6% versus 62.5%, P=0.063), but it did not differ in diabetic and/or overweight/obese patients with chronic hepatitis B or chronic hepatitis C. CONCLUSIONS: Hepatic steatosis in HBeAg-negative chronic hepatitis B (a) is less frequent than in genotype-1 chronic hepatitis C, (b) is mainly associated with presence of host metabolic factors, such as high body mass index and diabetes and (c) does not seem to be associated with the severity of liver histological lesions.

Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Publishing Authors By Initials

E Tsochatzis,GV Papatheodoridis,EK Manesis,N Chrysanthos,G Kafiri,AJ Archimandritis,E Tsochatzis,GV Papatheodoridis,EK Manesis,N Chrysanthos,G Kafiri,AJ Archimandritis,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Digestive and liver disease : official journal of

VOLUME: 39

Page Numbers: 936-42

Journal Abbreviation:

ISSN: 1590-8658

DAY: 27

MONTH: 08

YEAR: 2007

Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100958385

Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C.

AFFILIATION: 2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, 114 Vas. Sophias Ave., 11527 Athens, Greece.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Dig Liver Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C Related Publications

• A 70-year-old stock-breeder with tricuspid valve and defibrillator lead brucella endocarditis.
• Adipokines and insulin resistance in chronic hepatitis C.
• Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation.
• An extranodal NK/T cell lymphoma, nasal type, with specific immunophenotypic and genotypic features.
• Angioimmunoblastic T-cell lymphoma-associated arthritis: case report and literature review.
• Campylobacter fetus bacteraemia in a healthy individual: clinical and therapeutical implications.
• Changes of liver and muscle enzymes activity in patients with rigor.
• Epidemiological evidence for the non-random clustering of the components of the metabolic syndrome: multicentre study of the Mediterranean Group for the Study of Diabetes.
• Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C.
• Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis.
• Myelodysplastic syndrome presenting as acquired ichthyosis.
• Performance Characteristics of Microparticle Enzyme and Chemiluminescence Immunoassays for Measurement of Anti-HBc Immunoglobulin M in Sera of Patients with HBeAg-Negative Chronic Hepatitis B Virus Infection.
• Pseudohyperkalemia in serum: a new insight into an old phenomenon.
• Sensorineural hearing loss complicating severe rickettsial diseases: report of two cases.
• Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity.
• Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection.
• Severe rhabdomyolysis with hypoglycemia in an adult patient with carnitine palmitoyltransferase II deficiency.
• Systemic Vasculitis With Gastrointestinal Involvement in an HIV-Infected Adult.
• Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.
• Usefulness of enzyme-linked immunosorbent assay (elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. Addendum.
• Usefulness of enzyme-linked immunospot assay (elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.